Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04388371 · ClinicalTrials.gov registry record · Phase 1
Glutamine PET Imaging in LAM
A Phase 1 study of Lymphangioleiomyomatosis (LAM), sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04388371 is a Phase 1 study of Lymphangioleiomyomatosis (LAM) that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 5 participants, below the 50-participant average among 3 other Lymphangioleiomyomatosis (LAM) trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04388371, a Phase 1 study of Lymphangioleiomyomatosis (LAM), has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, subjects with spontaneous or tuberous sclerosis complex associated lymphangioleiomyomatosis (LAM) who have not been started on therapy with mTOR inhibitors such as sirolimus or everolimus to undergo a PET/CT scan using an novel PET tracer that may better evaluate disease activity in LAM subjects both before and after the initiation of mTOR inhibitor therapy will be enrolled. The procedure for each scan will be similar, involving one administration of the novel tracer C11-glutamine followed by a whole body PET/CT scan.
Conditions Studied
Interventions
- DRUG Glutamine
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-10-18 |
| Est. Completion | 2021-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04388371
The ClinicalTrials.gov registry entry for NCT04388371 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 50-participant average among 3 other Lymphangioleiomyomatosis (LAM) trials with a reported enrollment target (90% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphangioleiomyomatosis (LAM) appearing as the primary indexed condition, and to 1 intervention - of which Glutamine is the first listed.
NCT04388371 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT04388371 about?
NCT04388371 is a clinical study titled "Glutamine PET Imaging in LAM". In this study, subjects with spontaneous or tuberous sclerosis complex associated lymphangioleiomyomatosis (LAM) who have not been started on therapy with mTOR inhibitors such as sirolimus or everolimus to undergo a PET/CT scan using an novel PET tracer that may better evaluate disease activity in L...
What is the current status of trial NCT04388371?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-10-18. Estimated completion is 2021-08-10.
What conditions does trial NCT04388371 study?
This clinical trial studies the following conditions: Lymphangioleiomyomatosis (LAM).
What interventions are being tested in trial NCT04388371?
The interventions under investigation include: Glutamine (DRUG).
Who is sponsoring clinical trial NCT04388371?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04388371 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphangioleiomyomatosis (LAM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
RECRUITING · Phase 1
-
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
COMPLETED · Phase 3
-
COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.